AIM To determine a panel of serum micro RNAs(mi RNAs) that could be used as novel biomarkers for diagnosis of hepatocellular carcinoma(HCC).METHODS We initially screened 9 out of 754 serum mi RNAs by Taq Man Low Densi...AIM To determine a panel of serum micro RNAs(mi RNAs) that could be used as novel biomarkers for diagnosis of hepatocellular carcinoma(HCC).METHODS We initially screened 9 out of 754 serum mi RNAs by Taq Man Low Density Array in two pooled samples respectively from 35 HCC and 35 normal controls, and then validated individually by RT-qP CR in another 114 patients and 114 controls arranged in two phases. The changes of the selected mi RNAs after operation and their prognostic value were examined.RESULTS miR-375, miR-10 a, miR-122 and miR-423 were found to be significantly higher in HCC than in controls(P < 0.0001), and the area under the receiver-operating-characteristic curve for the 4-miR NA panel was 0.995(95%CI: 0.985-1). All the four mi RNAs were significantly reduced after surgical removal of the tumors(P < 0.0001), while still higher than normal controls(at least P < 0.05)CONCLUSION The four serum miR NAs(miR-375, miR-10 a, miR-122 and miR-423) could potentially serve as novel biomarkers for the diagnostic and prognostic of HCC.展开更多
Background:Recent studies have demonstrated that microRNAs(miRNAs)in the blood circulation can serve as promising diagnostic markers for cancers.This four-stage study aimed at finding serum miRNAs as potential biomark...Background:Recent studies have demonstrated that microRNAs(miRNAs)in the blood circulation can serve as promising diagnostic markers for cancers.This four-stage study aimed at finding serum miRNAs as potential biomarkers for lung adenocarcinoma(LA)diagnosis.Methods:The study was carried out between 2016 and 2017.The Exiqon miRNA qPCR panel(3 LA vs.1 normal control[NC]pooled serum samples)was used for initial screening to acquire miRNA profiles.Thirty-five dysregulated miRNAs were further evaluated in the training(24 LA vs.24 NCs)and testing stages(110 LA vs.110 NCs)using quantitative real-time polymerase chain reaction assays.Results:Four serum miRNAs(miR-133a-3p,miR-584-5p,miR-10b-5p,and miR-221-3p)were significantly overexpressed in LA patients compared with NCs.The diagnostic value of the four-miRNA panel was validated by an external cohort(36 LA vs.36 NCs).The areas under the receiver operating characteristic curve of the four-miRNA panel in the training,testing,and external validation stages were 0.734,0.803,and 0.894 respectively.Meanwhile,the expression level of miR-221-3p was much higher in LA tumor samples than that in the adjacent normal tissues(19 LA vs.19 NCs).The expression level of miR-10b-5p was also elevated in the serum-derived exosomes samples(18 LA vs.18 NCs).The expression of miR-133a-3p,miR-584-5p,and miR-10b-5p was significantly elevated in LA patients with epidermal growth factor receptor mutation compared with NCs.Conclusion:The study established a four-miRNA signature in serum that could improve the diagnostic capability of LA.展开更多
Objective To explore the differences of serum miRNA expression between patients with newly diagnosed type 2 diabetes mellitus(T2DM)and healthy people;analyze the expression of miRNA-19a before and after Liraglutide tr...Objective To explore the differences of serum miRNA expression between patients with newly diagnosed type 2 diabetes mellitus(T2DM)and healthy people;analyze the expression of miRNA-19a before and after Liraglutide treatment,and to analyze the association between miRNA-19a and pancreaticβcells’function.展开更多
AIM:To investigate whether circulating microRNAs (miRNAs) can serve as molecular markers to predict liver injury resulted from chronic hepatitis B (CHB). METHODS:The profiles of serum miRNA expression were first gener...AIM:To investigate whether circulating microRNAs (miRNAs) can serve as molecular markers to predict liver injury resulted from chronic hepatitis B (CHB). METHODS:The profiles of serum miRNA expression were first generated with serum samples collected from 10 patients with CHB and 10 healthy donors (Ctrls) by microarray analysis. The levels of several miRNAs were further quantitated by real-time reverse transcriptionpolymerase chain reaction with serum samples from another 24 CHB patients and 24 Ctrls. Serum samples of 20 patients with nonalcohlic steatohepatitis (NASH) were also included for comparison. The comparison in the levels of miRNAs between groups (CHB, NASH and Ctrl) was analyzed with Mann-Whitney Utest. The correlation between miRNAs and clinical pathoparameters was analyzed using Spearman correlation analysis or canonical correlation analysis. The receiver-operator characteristic (ROC) curves were also generated to determine the specificity and sensitivity of each individual miRNA in distinguishing patients with CHB from Ctrls. RESULTS:miRNA profile analysis showed that 34 miRNAs were differentially expressed between CHB and Ctrl subjects, in which 12 were up-regulated and 22 down-regulated in CHB subject (fold change > 2.0 and P < 0.01). The median levels of miR-122, -572, -575 and -638 were significantly higher (P < 1.00 × 10 -5 ) while miR-744 significantly lower (P < 1.00 × 10 -6 ) in CHB compared with the Ctrl. The levels of miR-122, -572 and -638 were also higher (P < 1.00 × 10 -3 ) while the level of miR-744 lower in CHB (P < 0.05) than in NASH, although the difference between them was not as significant as that between CHB and Ctrl. ROC curve analysis revealed that the levels of miR-122, -572, -575, -638 and -744 in serum were sensitive and specific enough to distinguish CHB, NASH and Ctrl. Multivariate analysis further showed that the levels of these miRNAs were correlated with the liver function parameters. Most significantly, it was the scatter plot of principal component with the levels of these miRNAs, but not the parameters of liver function, which clearly distinguished CHB, NASH and Ctrl subjects. CONCLUSION:Serum levels of miR-122, -572, -575, -638 and -744 are deregulated in patients with CHB or NASH. The levels of these miRNAs may serve as potential biomarkers for liver injury caused by CHB and NASH.展开更多
MicroRNAs(miRs) have been shown to be differentially expressed in the serum of cancer patients and controls,and can thus be used as biomarkers for cancer screening.We detected the expression level of miR-155 in the se...MicroRNAs(miRs) have been shown to be differentially expressed in the serum of cancer patients and controls,and can thus be used as biomarkers for cancer screening.We detected the expression level of miR-155 in the serum of female breast cancer patients and healthy controls to investigate whether serum miR-155 could discriminate patients with early-stage breast cancer.Serum samples were collected from 20 female patients with newly diagnosed breast cancer and 10 healthy controls.Real-time quantitative PCR was used to detect the expression level of miR-155.The expression level of miR-155 was significantly increased in the serum of breast cancer patients compared with in the serum of normal controls.MiR-155 may be useful as a blood-based biomarker for breast cancer screening.展开更多
基金Supported by the National Key R&D Program of China,No.2016YFC0106604National Natural Science Foundation of China,No.81502591
文摘AIM To determine a panel of serum micro RNAs(mi RNAs) that could be used as novel biomarkers for diagnosis of hepatocellular carcinoma(HCC).METHODS We initially screened 9 out of 754 serum mi RNAs by Taq Man Low Density Array in two pooled samples respectively from 35 HCC and 35 normal controls, and then validated individually by RT-qP CR in another 114 patients and 114 controls arranged in two phases. The changes of the selected mi RNAs after operation and their prognostic value were examined.RESULTS miR-375, miR-10 a, miR-122 and miR-423 were found to be significantly higher in HCC than in controls(P < 0.0001), and the area under the receiver-operating-characteristic curve for the 4-miR NA panel was 0.995(95%CI: 0.985-1). All the four mi RNAs were significantly reduced after surgical removal of the tumors(P < 0.0001), while still higher than normal controls(at least P < 0.05)CONCLUSION The four serum miR NAs(miR-375, miR-10 a, miR-122 and miR-423) could potentially serve as novel biomarkers for the diagnostic and prognostic of HCC.
基金grants from the National Natural Science Foundation of China(No.81672400,and No.81672788)Natural Science Foundation of Jiangsu Provincial Department of Education(No.17KJB320007)CSCO-Hausoh Cancer Research Foundation(No.YHS2017-032)。
文摘Background:Recent studies have demonstrated that microRNAs(miRNAs)in the blood circulation can serve as promising diagnostic markers for cancers.This four-stage study aimed at finding serum miRNAs as potential biomarkers for lung adenocarcinoma(LA)diagnosis.Methods:The study was carried out between 2016 and 2017.The Exiqon miRNA qPCR panel(3 LA vs.1 normal control[NC]pooled serum samples)was used for initial screening to acquire miRNA profiles.Thirty-five dysregulated miRNAs were further evaluated in the training(24 LA vs.24 NCs)and testing stages(110 LA vs.110 NCs)using quantitative real-time polymerase chain reaction assays.Results:Four serum miRNAs(miR-133a-3p,miR-584-5p,miR-10b-5p,and miR-221-3p)were significantly overexpressed in LA patients compared with NCs.The diagnostic value of the four-miRNA panel was validated by an external cohort(36 LA vs.36 NCs).The areas under the receiver operating characteristic curve of the four-miRNA panel in the training,testing,and external validation stages were 0.734,0.803,and 0.894 respectively.Meanwhile,the expression level of miR-221-3p was much higher in LA tumor samples than that in the adjacent normal tissues(19 LA vs.19 NCs).The expression level of miR-10b-5p was also elevated in the serum-derived exosomes samples(18 LA vs.18 NCs).The expression of miR-133a-3p,miR-584-5p,and miR-10b-5p was significantly elevated in LA patients with epidermal growth factor receptor mutation compared with NCs.Conclusion:The study established a four-miRNA signature in serum that could improve the diagnostic capability of LA.
文摘Objective To explore the differences of serum miRNA expression between patients with newly diagnosed type 2 diabetes mellitus(T2DM)and healthy people;analyze the expression of miRNA-19a before and after Liraglutide treatment,and to analyze the association between miRNA-19a and pancreaticβcells’function.
基金Acknowledgments We thank Drs Fengyong Liu and Sheng Luan at UC Berkeley, USA, for their discussion and help with the writing of the manuscript. This work was supported by grants from the National Natural Science Foundation of China （no. 30225037, 30471991, 30570731）, National Basic Research Program of China （973 Program） （no. 2006CB503909, 2004CB518603）, the ＂111＂ Project, and the Natural Science Foundation of Jiangsu Province （no. BK2004082, BK2006714）.
基金Supported by National Science and Technology Major Project of China, No. 2012ZX10005001-004Leading Academic Discipline Project of Shanghai Municipal Education Commission, No.J50301+1 种基金Doctoral Fund of Ministry of Education of China, No.20093107120010E-institutes of Shanghai Municipal Education Commission, No. E03008
文摘AIM:To investigate whether circulating microRNAs (miRNAs) can serve as molecular markers to predict liver injury resulted from chronic hepatitis B (CHB). METHODS:The profiles of serum miRNA expression were first generated with serum samples collected from 10 patients with CHB and 10 healthy donors (Ctrls) by microarray analysis. The levels of several miRNAs were further quantitated by real-time reverse transcriptionpolymerase chain reaction with serum samples from another 24 CHB patients and 24 Ctrls. Serum samples of 20 patients with nonalcohlic steatohepatitis (NASH) were also included for comparison. The comparison in the levels of miRNAs between groups (CHB, NASH and Ctrl) was analyzed with Mann-Whitney Utest. The correlation between miRNAs and clinical pathoparameters was analyzed using Spearman correlation analysis or canonical correlation analysis. The receiver-operator characteristic (ROC) curves were also generated to determine the specificity and sensitivity of each individual miRNA in distinguishing patients with CHB from Ctrls. RESULTS:miRNA profile analysis showed that 34 miRNAs were differentially expressed between CHB and Ctrl subjects, in which 12 were up-regulated and 22 down-regulated in CHB subject (fold change > 2.0 and P < 0.01). The median levels of miR-122, -572, -575 and -638 were significantly higher (P < 1.00 × 10 -5 ) while miR-744 significantly lower (P < 1.00 × 10 -6 ) in CHB compared with the Ctrl. The levels of miR-122, -572 and -638 were also higher (P < 1.00 × 10 -3 ) while the level of miR-744 lower in CHB (P < 0.05) than in NASH, although the difference between them was not as significant as that between CHB and Ctrl. ROC curve analysis revealed that the levels of miR-122, -572, -575, -638 and -744 in serum were sensitive and specific enough to distinguish CHB, NASH and Ctrl. Multivariate analysis further showed that the levels of these miRNAs were correlated with the liver function parameters. Most significantly, it was the scatter plot of principal component with the levels of these miRNAs, but not the parameters of liver function, which clearly distinguished CHB, NASH and Ctrl subjects. CONCLUSION:Serum levels of miR-122, -572, -575, -638 and -744 are deregulated in patients with CHB or NASH. The levels of these miRNAs may serve as potential biomarkers for liver injury caused by CHB and NASH.
基金supported by the Jiangsu Provincial Hospital of TCM
文摘MicroRNAs(miRs) have been shown to be differentially expressed in the serum of cancer patients and controls,and can thus be used as biomarkers for cancer screening.We detected the expression level of miR-155 in the serum of female breast cancer patients and healthy controls to investigate whether serum miR-155 could discriminate patients with early-stage breast cancer.Serum samples were collected from 20 female patients with newly diagnosed breast cancer and 10 healthy controls.Real-time quantitative PCR was used to detect the expression level of miR-155.The expression level of miR-155 was significantly increased in the serum of breast cancer patients compared with in the serum of normal controls.MiR-155 may be useful as a blood-based biomarker for breast cancer screening.
